Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060333 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
A Phase 2 study of Recurrent Melanoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 20
- Study locations
NCT00060333 is a Phase 2 study of Recurrent Melanoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 20 participants, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00060333, a Phase 2 study of Recurrent Melanoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial is studying how well adjuvant radiation therapy works in treating patients who have undergone surgery for desmoplastic melanoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surgery.
Conditions Studied
Interventions
- RADIATION radiation therapy
Study Locations (20)
Iowa
- Mercy Capitol Hospital - Des Moines
- CCOP - Iowa Oncology Research Association - Des Moines
- John Stoddard Cancer Center at Iowa Methodist Medical Center - Des Moines
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center - Des Moines
- Medical Oncology and Hematology Associates at Mercy Cancer Center - Des Moines
- Mercy Cancer Center at Mercy Medical Center - Des Moines - Des Moines
- John Stoddard Cancer Center at Iowa Lutheran Hospital - Des Moines
- McCreery Cancer Center at Ottumwa Regional - Ottumwa
- Siouxland Hematology-Oncology Associates, LLP - Sioux City
- Mercy Medical Center - Sioux City - Sioux City
- St. Luke's Regional Medical Center - Sioux City
Minnesota
- Fairview Ridges Hospital - Burnsville
- Mercy and Unity Cancer Center at Mercy Hospital - Coon Rapids
- Fairview Southdale Hospital - Edina
- Mercy and Unity Cancer Center at Unity Hospital - Fridley
- Minnesota Oncology Hematology, PA - Maplewood - Maplewood
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital - Minneapolis
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Illinois
- Joliet Oncology-Hematology Associates, Limited - West - Joliet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060333
The ClinicalTrials.gov registry entry for NCT00060333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 23 other Recurrent Melanoma trials with a reported enrollment target (88% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Melanoma appearing as the primary indexed condition, and to 1 intervention - of which radiation therapy is the first listed.
NCT00060333 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Iowa, Minnesota, Arizona.
Frequently Asked Questions
What is clinical trial NCT00060333 about?
NCT00060333 is a clinical study titled "Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma". This phase II trial is studying how well adjuvant radiation therapy works in treating patients who have undergone surgery for desmoplastic melanoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surger...
What is the current status of trial NCT00060333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-07. Estimated completion is 2016-04.
What conditions does trial NCT00060333 study?
This clinical trial studies the following conditions: Recurrent Melanoma.
What interventions are being tested in trial NCT00060333?
The interventions under investigation include: radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00060333?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00060333 being conducted?
This trial has 20 study locations across Arizona, Florida, Illinois, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dinaciclib in Treating Patients With Stage IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
COMPLETED · Phase 2
-
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.